| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Steroid Hormones Section (G.G., D.S., J.E.W.M., S.S.S.) Laboratory of Molecular and Cellular Biology National Institute of Diabetes, Digestive and Kidney Diseases and the Laboratory of Receptor Biology and Gene Expression (C.L.S.) National Cancer Institute/Division of Basic Sciences National Institutes of Health Bethesda, Maryland 20892-0805
A pharmacologically relevant property of steroid hormone-regulated gene induction is the partial agonist activity of antisteroid complexes. We now report that dexamethasone-mesylate (Dex-Mes) and dexamethasone-oxetanone (Dex-Ox), each a derivative of the glucocorticoid-selective steroid dexamethasone (Dex), are two new antiprogestins with significant amounts of agonist activity with both the A and B isoforms of progesterone receptor (PR), for different progesterone-responsive elements, and in several cell lines. These compounds continue to display activity under conditions where another partial antiprogestin (RTI-020) is inactive. These new antiprogestins were used to determine whether the partial agonist activity of PR complexes can be modified by changing concentrations of receptor or coregulator, as we have recently demonstrated for glucocorticoid receptors (GRs). Because GR and coregulator concentrations simultaneously altered the position of the physiologically relevant dose-response curve, and associated EC50, of GR-agonist complexes, we also examined this phenomenon with PR. We find that elevated PR or transcriptional intermediary factor 2 (TIF2) concentrations increase the partial agonist activity of Dex-Mes and Dex-Ox, and the EC50 of agonists, independently of changes in total gene transactivation. Furthermore, the corepressors SMRT (silencing mediator for retinoid and thyroid receptors) and NCoR (nuclear receptor corepressor) each suppresses gene induction but NCoR acts opposite to SMRT and, like the coactivator TIF2, reduces the EC50 and increases the partial agonist activity of antiprogestins. These comparable responses of GR and PR suggest that variations in receptor and coregulator concentrations may be a general mechanism for altering the induction properties of other steroid receptors. Finally, the magnitude of coregulator effects on PR induction properties are often not identical for agonists and the new antagonists, suggesting subtle mechanistic differences. These properties of Dex-Mes and Dex-Ox, plus the sensitivity of their activity to cellular differences in PR and coregulator concentrations, make these steroids potential new SPRMs (selective progesterone receptor modulators) that should prove useful as probes of PR induction properties.
This article has been cited by other articles:
 |
|
 |
|
  M. A. Behera, Q. Dai, R. Garde, C. Saner, E. Jungheim, and T. M. Price Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1089 - E1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. De Amicis, S. Zupo, M. L. Panno, R. Malivindi, F. Giordano, I. Barone, L. Mauro, S. A. W. Fuqua, and S. Ando Progesterone Receptor B Recruits a Repressor Complex to a Half-PRE Site of the Estrogen Receptor {alpha} Gene Promoter Mol. Endocrinol., April 1, 2009; 23(4): 454 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wilkinson, S. Hayes, D. Thompson, P. Whitney, and K. Bi Compound Profiling Using a Panel of Steroid Hormone Receptor Cell-Based Assays J Biomol Screen, September 1, 2008; 13(8): 755 - 765. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Li, M. E Andersen, S. Heber, and Q. Zhang Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression J. Mol. Endocrinol., May 1, 2007; 38(5): 569 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. He and S. S. Simons Jr. STAMP, a Novel Predicted Factor Assisting TIF2 Actions in Glucocorticoid Receptor-Mediated Induction and Repression Mol. Cell. Biol., February 15, 2007; 27(4): 1467 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang and S. S. Simons Jr. Corepressor Binding to Progesterone and Glucocorticoid Receptors Involves the Activation Function-1 Domain and Is Inhibited by Molybdate Mol. Endocrinol., June 1, 2005; 19(6): 1483 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis Endocr. Rev., May 1, 2005; 26(3): 423 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cho, B. L. Kagan, J. A. Blackford Jr., D. Szapary, and S. S. Simons Jr. Glucocorticoid Receptor Ligand Binding Domain Is Sufficient for the Modulation of Glucocorticoid Induction Properties by Homologous Receptors, Coactivator Transcription Intermediary Factor 2, and Ubc9 Mol. Endocrinol., February 1, 2005; 19(2): 290 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, J. A. Blackford Jr., L.-N. Song, Y. Huang, S. Cho, and S. S. Simons Jr. Equilibrium Interactions of Corepressors and Coactivators with Agonist and Antagonist Complexes of Glucocorticoid Receptors Mol. Endocrinol., June 1, 2004; 18(6): 1376 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Smith and B. W. O'Malley Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators Endocr. Rev., February 1, 2004; 25(1): 45 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. He, D. Szapary, and S. S. Simons Jr. Modulation of Induction Properties of Glucocorticoid Receptor-Agonist and -Antagonist Complexes by Coactivators Involves Binding to Receptors but Is Independent of Ability of Coactivators to Augment Transactivation J. Biol. Chem., December 13, 2002; 277(51): 49256 - 49266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sathya, M. S. Jansen, S. C. Nagel, C. E. Cook, and D. P. MCDonnell Identification and Characterization of Novel Estrogen Receptor-{beta}-Sparing Antiprogestins Endocrinology, August 1, 2002; 143(8): 3071 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schulz, M. Eggert, A. Baniahmad, A. Dostert, T. Heinzel, and R. Renkawitz RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding J. Biol. Chem., July 12, 2002; 277(29): 26238 - 26243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, S. Kaul, and S. S. Simons Jr. Structure/Activity Elements of the Multifunctional Protein, GMEB-1. CHARACTERIZATION OF DOMAINS RELEVANT FOR THE MODULATION OF GLUCOCORTICOID RECEPTOR TRANSACTIVATION PROPERTIES J. Biol. Chem., June 7, 2002; 277(24): 22053 - 22062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-N. Song, B. Huse, S. Rusconi, and S. S. Simons Jr. Transactivation Specificity of Glucocorticoid Versus Progesterone Receptors. ROLE OF FUNCTIONALLY DIFFERENT INTERACTIONS OF TRANSCRIPTION FACTORS WITH AMINO- AND CARBOXYL-TERMINAL RECEPTOR DOMAINS J. Biol. Chem., June 29, 2001; 276(27): 24806 - 24816. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
